11 Einträge |
Seite 1 / 1
![]() |
The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial. |
Fitzal F, Filipits M, Rudas M, Greil R, Dietze O, Samonigg H, Lax S, Herz W, Dubsky P, Bartsch R, Kronenwett R, Gnant M |
British journal of cancer. 2015 Mar 24. pii: bjc201598. doi: 10.1038/bjc.2015.98. pmc: PMC4402462 |
PMID: 25867274 |
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. |
Dubsky P, Brase JC, Jakesz R, Rudas M, Singer CF, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann MC, Petry C, Weber KE, Fisch K, Kronenwett R, Gnant M, Filipits M |
British journal of cancer. 2013 Oct 24. pii: bjc2013671. doi: 10.1038/bjc.2013.671. pmc: PMC3859949 |
PMID: 24157828 |
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. |
Dubsky P, Filipits M, Jakesz R, Rudas M, Singer CF, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann MC, Petry C, Weber KE, Kronenwett R, Brase JC, Gnant M |
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2012 Oct 3. pii: mds334. doi: 10.1093/annonc/mds334. pmc: PMC3574544 |
PMID: 23035151 |
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. |
Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer C, Müller V, Jänicke F, Schmidt M, Kölbl H, Rody A, Kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE, Feder IS, Hennig G, Kronenwett R, Gehrmann M, Gnant M |
Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Aug 1. pii: 1078-0432.CCR-11-0926. doi: 10.1158/1078-0432.CCR-11-0926 |
PMID: 21807638 |
Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. |
Buus R, Sestak I, Kronenwett R, Denkert C, Dubsky P, Krappmann K, Scheer M, Petry C, Cuzick J, Dowsett M |
Journal of the National Cancer Institute. 2016 Jul 10. pii: djw149. doi: 10.1093/jnci/djw149 |
PMID: 27400969 |
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. |
Sestak I, Buus R, Cuzick J, Dubsky P, Kronenwett R, Denkert C, Ferree S, Sgroi D, Schnabel C, Baehner FL, Mallon E, Dowsett M |
JAMA oncology. 2018 Feb 15. pii: 2672388. doi: 10.1001/jamaoncol.2017.5524 |
PMID: 29450494 |
Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. |
Sestak I, Martín M, Dubsky P, Kronenwett R, Rojo F, Cuzick J, Filipits M, Ruiz A, Gradishar W, Soliman H, Schwartzberg L, Buus R, Hlauschek D, Rodríguez-Lescure A, Gnant M |
Breast cancer research and treatment. 2019 Apr 30. doi: 10.1007/s10549-019-05226-8. pii: 10.1007/s10549-019-05226-8 |
PMID: 31041683 |
Prediction of Distant Recurrence using EndoPredict among Women with ER+, HER2- Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. |
Filipits M, Dubsky P, Rudas M, Greil R, Balic M, Bago-Horvath Z, Singer CF, Hlauschek D, Brown K, Bernhisel R, Kronenwett R, Lancaster JM, Fitzal F, Gnant M |
Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 May 7. pii: 1078-0432.CCR-19-0376. doi: 10.1158/1078-0432.CCR-19-0376 |
PMID: 31064782 |
Prognostic value of endopredict for invasive lobular carcinomas in the combined ABCSG-6/8 and TransATAC trials. |
Sestak I, Filipits M, Buus R, Rudas M, Knauer M, Kronenwett R, Cuzick J, Gnant MI, Dowsett M, Dubsky P |
Annals of oncology : official journal of the European Society for Medical Oncology. 2020 Jan 8. pii: S0923-7534(19)30274-1. doi: 10.1093/annonc/mdz095.001 |
PMID: 32084704 |
The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial. |
Dubsky PC, Singer CF, Egle D, Wette V, Petru E, Balic M, Pichler A, Greil R, Petzer AL, Bago-Horvath Z, Fesl C, Meek SM, Kronenwett R, Rudas M, Gnant M, Filipits M |
European journal of cancer (Oxford, England : 1990). 2020 Jun 2. pii: S0959-8049(20)30223-9. doi: 10.1016/j.ejca.2020.04.020 |
PMID: 32502940 |
Prognostic Value of EndoPredict in Women with Hormone Receptor Positive, HER2-Negative Invasive Lobular Breast Cancer. |
Sestak I, Filipits M, Buus R, Rudas M, Balic M, Knauer M, Kronenwett R, Fitzal F, Cuzick J, Gnant M, Greil R, Dowsett M, Dubsky P |
Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Jun 19. pii: 1078-0432.CCR-20-0260. doi: 10.1158/1078-0432.CCR-20-0260 |
PMID: 32561662 |
11 Einträge |
Seite 1 / 1
![]() |